Enterprise Value
141.8M
Cash
421.2M
Avg Qtr Burn
-52.63M
Short % of Float
5.39%
Insider Ownership
5.70%
Institutional Own.
80.45%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 3 Data readout | ||
Phase 3 Data readout | ||
KSI-301 (BEACON) Details Retinal vein occlusion | Phase 3 Update | |
KSI-301 (DAZZLE) Details Wet age-related macular degeneration Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2/3 Data readout | |
KSI-501 (anti-VEGF) Details Diabetic macular edema, Eye disease | Phase 1 Data readout |